Proactive Investors - Run By Investors For Investors

AusCann Group appoints Paul MacLeman as executive director

AusCann is transitioning from a start-up company focused on product development to a pharmaceutical production and sales business.
Dr Paul MacLeman
Dr MacLeman has over 25 years’ board and executive experience

AusCann Group Holdings Ltd (ASX:AC8) (OTCQX:ACNNF) has appointed experienced pharmaceutical executive, Dr Paul MacLeman, to the board as an executive director.

Dr MacLeman has over 25 years’ board and executive experience across the life sciences, agricultural and not for profit sectors.

This includes strategy formulation, capital raising, business development, technology commercialisation and sales & marketing.

He has also launched a variety of products in Australia, the US and Asia, founded life sciences start-ups in the biologics area and worked in investment banking.

READ: Auscann Group makes steady progress towards production of cannabinoid medicines

AusCann chairman Dr Mal Washer said: “I am delighted that Paul has joined the AusCann Board.

“He has an in-depth understanding of the AusCann business through his existing engagement since October 2017 and his ongoing contribution to the company’s pharmaceutical development activities, culminating in our patent application for a new final dose form cannabinoid therapeutic.

“His extensive experience in the pharmaceutical industry will be a valuable asset as we move forward.

“Paul is also well placed to lead the executive search process to find a new CEO for AusCann’s next phase of development into a pharmaceutical manufacturing and sales business.”

READ: AusCann Group commences trading in the US increasing global exposure

AusCann managing director Elaine Darby has advised the board she intends to step down as managing director as part of the company’s transition to a sales-focused pharmaceutical company.

The board will now commence a comprehensive executive search to recruit a suitable candidate.

Darby will continue in her role to ensure an orderly transition process until an appropriate time to hand over leadership responsibilities.

READ: AusCann Group well positioned as investors move in on medical cannabis sector

AusCann chairman Mal Washer said: “I am very pleased with the substantial progress the company has made under Elaine’s leadership over the past few years.

“We have positioned ourselves as a leader with the successful development of our new dose form cannabinoid pharmaceutical for the control of chronic pain.

“The Board thanks Elaine for her essential role in taking AusCann from a small start-up company through to one of the leading companies in medical cannabis listed on the ASX.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 31 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.
cannabis plant
Sat
The Vancouver-based cannabis group services medical and recreational cannabis markets in Canada and internationally

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use